How Dietary Fibre, Acting via the Gut Microbiome, Lowers Blood Pressure.

IF 3.9 2区医学 Q1 PERIPHERAL VASCULAR DISEASE Current Hypertension Reports Pub Date : 2022-11-01 Epub Date: 2022-07-15 DOI:10.1007/s11906-022-01216-2

Chudan Xu, Francine Z Marques

{"title":"How Dietary Fibre, Acting via the Gut Microbiome, Lowers Blood Pressure.","authors":"Chudan Xu, Francine Z Marques","doi":"10.1007/s11906-022-01216-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: To discuss the interplay behind how a high-fibre diet leads to lower blood pressure (BP) via the gut microbiome.Recent findings: Compelling evidence from meta-analyses support dietary fibre prevents the development of cardiovascular disease and reduces BP. This relation is due to gut microbial metabolites, called short-chain fatty acids (SCFAs), derived from fibre fermentation. The SCFAs acetate, propionate and butyrate lower BP in independent hypertensive models. Mechanisms are diverse but still not fully understood-for example, they include G protein-coupled receptors, epigenetics, immune cells, the renin-angiotensin system and vasculature changes. Lack of dietary fibre leads to changes to the gut microbiota that drive an increase in BP. The mechanisms involved are unknown. The intricate interplay between fibre, the gut microbiota and SCFAs may represent novel therapeutic approaches for high BP. Other gut microbiota-derived metabolites, produced when fibre intake is low, may hold potential therapeutic applications. Further translational evidence is needed.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568477/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-022-01216-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To discuss the interplay behind how a high-fibre diet leads to lower blood pressure (BP) via the gut microbiome.

Recent findings: Compelling evidence from meta-analyses support dietary fibre prevents the development of cardiovascular disease and reduces BP. This relation is due to gut microbial metabolites, called short-chain fatty acids (SCFAs), derived from fibre fermentation. The SCFAs acetate, propionate and butyrate lower BP in independent hypertensive models. Mechanisms are diverse but still not fully understood-for example, they include G protein-coupled receptors, epigenetics, immune cells, the renin-angiotensin system and vasculature changes. Lack of dietary fibre leads to changes to the gut microbiota that drive an increase in BP. The mechanisms involved are unknown. The intricate interplay between fibre, the gut microbiota and SCFAs may represent novel therapeutic approaches for high BP. Other gut microbiota-derived metabolites, produced when fibre intake is low, may hold potential therapeutic applications. Further translational evidence is needed.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

膳食纤维如何通过肠道微生物群降低血压？

综述的目的：讨论高纤维饮食如何通过肠道微生物组降低血压（BP）背后的相互作用：荟萃分析的有力证据表明，膳食纤维可预防心血管疾病的发生并降低血压。这种关系是由于纤维发酵产生的肠道微生物代谢产物，即短链脂肪酸（SCFAs）。在独立的高血压模型中，SCFAs 乙酸酯、丙酸酯和丁酸酯可降低血压。其机制多种多样，但仍未完全明了--例如，它们包括 G 蛋白偶联受体、表观遗传学、免疫细胞、肾素-血管紧张素系统和血管变化。缺乏膳食纤维会导致肠道微生物群发生变化，从而导致血压升高。其中的机制尚不清楚。纤维、肠道微生物群和 SCFAs 之间错综复杂的相互作用可能是治疗高血压的新方法。纤维摄入量低时产生的其他肠道微生物群衍生代谢物可能具有潜在的治疗用途。还需要进一步的转化证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Hypertension Reports 医学-外周血管病

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.